BioCardia (BCDA) Competitors $1.88 -0.08 (-4.08%) Closing price 04:00 PM EasternExtended Trading$1.94 +0.06 (+2.98%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. ADVM, GANX, SKYE, DTIL, IKNA, KPTI, RENB, ARTV, OTLK, and VNRXShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Adverum Biotechnologies (ADVM), Gain Therapeutics (GANX), Skye Bioscience (SKYE), Precision BioSciences (DTIL), Ikena Oncology (IKNA), Karyopharm Therapeutics (KPTI), Renovaro (RENB), Artiva Biotherapeutics (ARTV), Outlook Therapeutics (OTLK), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Adverum Biotechnologies Gain Therapeutics Skye Bioscience Precision BioSciences Ikena Oncology Karyopharm Therapeutics Renovaro Artiva Biotherapeutics Outlook Therapeutics VolitionRx BioCardia (NASDAQ:BCDA) and Adverum Biotechnologies (NASDAQ:ADVM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do analysts recommend BCDA or ADVM? BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 1,229.79%. Adverum Biotechnologies has a consensus target price of $26.40, suggesting a potential upside of 1,063.00%. Given BioCardia's stronger consensus rating and higher probable upside, research analysts clearly believe BioCardia is more favorable than Adverum Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable valuation & earnings, BCDA or ADVM? BioCardia has higher earnings, but lower revenue than Adverum Biotechnologies. BioCardia is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$58K167.84-$11.57M-$2.33-0.81Adverum Biotechnologies$1M47.42-$117.17M-$6.40-0.35 Does the media favor BCDA or ADVM? In the previous week, Adverum Biotechnologies had 14 more articles in the media than BioCardia. MarketBeat recorded 18 mentions for Adverum Biotechnologies and 4 mentions for BioCardia. Adverum Biotechnologies' average media sentiment score of 0.12 beat BioCardia's score of -0.04 indicating that Adverum Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adverum Biotechnologies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is BCDA or ADVM more profitable? Adverum Biotechnologies has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets BioCardia-1,999.77% N/A -208.38% Adverum Biotechnologies N/A -65.14%-40.52% Does the MarketBeat Community prefer BCDA or ADVM? Adverum Biotechnologies received 356 more outperform votes than BioCardia when rated by MarketBeat users. However, 60.71% of users gave BioCardia an outperform vote while only 60.26% of users gave Adverum Biotechnologies an outperform vote. CompanyUnderperformOutperformBioCardiaOutperform Votes1760.71% Underperform Votes1139.29% Adverum BiotechnologiesOutperform Votes37360.26% Underperform Votes24639.74% Which has more risk and volatility, BCDA or ADVM? BioCardia has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Adverum Biotechnologies has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Do institutionals and insiders hold more shares of BCDA or ADVM? 20.6% of BioCardia shares are owned by institutional investors. Comparatively, 48.2% of Adverum Biotechnologies shares are owned by institutional investors. 20.0% of BioCardia shares are owned by company insiders. Comparatively, 4.2% of Adverum Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryAdverum Biotechnologies beats BioCardia on 10 of the 19 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.74M$2.93B$5.37B$8.38BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-0.4530.5026.8419.71Price / Sales167.84400.15392.34117.39Price / CashN/A168.6838.2534.62Price / Book-1.693.286.794.50Net Income-$11.57M-$72.17M$3.23B$248.18M7 Day Performance-32.13%4.28%4.07%1.14%1 Month Performance7.61%7.62%12.52%15.20%1 Year Performance-69.13%-28.15%16.83%6.56% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia2.5595 of 5 stars$1.88-4.1%$25.00+1,229.8%-66.7%$9.74M$58,000.00-0.4540News CoverageEarnings ReportADVMAdverum Biotechnologies3.7754 of 5 stars$2.71-3.6%$26.60+881.5%-69.7%$56.62M$1M-0.45190Analyst RevisionHigh Trading VolumeGANXGain Therapeutics1.9752 of 5 stars$1.92-1.0%$8.20+327.1%-23.9%$56.50M$50,000.00-1.7520News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpSKYESkye Bioscience1.1333 of 5 stars$2.07+19.4%$16.60+703.9%-83.6%$56.07MN/A-2.3211Analyst ForecastDTILPrecision BioSciences3.4803 of 5 stars$5.22+1.8%$47.00+800.4%-62.0%$55.07M$68.70M87.01200Earnings ReportAnalyst ForecastIKNAIkena Oncology2.8416 of 5 stars$1.14+0.9%$3.00+163.2%-19.3%$55.01M$659,000.00-0.9370Positive NewsKPTIKaryopharm Therapeutics3.8392 of 5 stars$6.15+2.3%$57.50+835.0%-69.8%$52.71M$145.24M-6.03380Gap DownRENBRenovaro0.8135 of 5 stars$0.32+2.4%N/A-70.1%$51.30MN/A-0.3520ARTVArtiva Biotherapeutics1.9338 of 5 stars$2.10+1.0%$20.40+871.4%N/A$51.16M$251,000.000.0081OTLKOutlook Therapeutics1.9873 of 5 stars$1.59+3.9%$10.20+541.5%-78.6%$50.91MN/A-0.2120Earnings ReportVNRXVolitionRx1.889 of 5 stars$0.49-1.0%$3.33+573.7%-33.7%$49.86M$1.23M-1.3780News CoverageGap Up Related Companies and Tools Related Companies ADVM Alternatives GANX Alternatives SKYE Alternatives DTIL Alternatives IKNA Alternatives KPTI Alternatives RENB Alternatives ARTV Alternatives OTLK Alternatives VNRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCDA Stock Free BCDA Stock Alerts